Biotech Values

[DewDiligence]

Thanks. Based on the paper you posted, I think now understand what Husseini Manji meant on JNJ’s webcast last week when he said that eliminating the assumption of linearity in a reanalysis of the phase-2 Bapi data gave the company greater confidence that the phase-3 program will succeed (#msg-63626970). As far as I can tell, this is a longwinded way of saying that the phase-2 efficacy measured at 78 weeks, specifically, was quite good even though the efficacy measured uniformly over the study period of 78 weeks (the prespecified primary analysis) was poor.

p.s. I wonder why Manji didn’t make his point in a way that was simple and understandable.